The pharmacological landscape for fibroids has been revolutionized by the introduction of new agents offering effective non-surgical management. Pharmacological Treatments are now dominated by oral GnRH (Gonadotropin-Releasing Hormone) antagonists, such as elagolix and relugolix, often administered in combination with low-dose estrogen and progestin ("add-back therapy"). These antagonists rapidly and dose-dependently suppress estrogen production, avoiding the initial hormone "flare-up" seen with older GnRH agonists, and the add-back therapy mitigates severe hypoestrogenic side effects like bone loss, enabling longer-term use for symptom control and fibroid shrinkage.

Another important class is Selective Progesterone Receptor Modulators (SPRMs), such as ulipristal acetate, which act by blocking progesterone's pro-growth effect on fibroid tissue. While GnRH antagonists primarily target heavy menstrual bleeding and overall size reduction, SPRMs are noted for their anti-proliferative and anti-fibrotic properties. These modern oral therapies provide patients with effective, uterus-sparing options to manage symptoms or to serve as a preoperative measure to shrink fibroids before surgical removal.

Related Reports